1546 related articles for article (PubMed ID: 29754190)
1. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
Clarke K; Chintanaboina J
Clin Rev Allergy Immunol; 2019 Oct; 57(2):179-193. PubMed ID: 29754190
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review and update on Crohn's disease.
Gajendran M; Loganathan P; Catinella AP; Hashash JG
Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
[TBL] [Abstract][Full Text] [Related]
4. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review.
Hashash JG; Elkins J; Lewis JD; Binion DG
Gastroenterology; 2024 Mar; 166(3):521-532. PubMed ID: 38276922
[TBL] [Abstract][Full Text] [Related]
5. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
6. Similar clinical characteristics of familial and sporadic inflammatory bowel disease in South Korea.
Chung SH; Park SJ; Lee HS; Hong SP; Cheon JH; Kim TI; Kim WH
World J Gastroenterol; 2014 Dec; 20(45):17120-6. PubMed ID: 25493025
[TBL] [Abstract][Full Text] [Related]
7. The Role of Diet in the Pathogenesis and Management of Inflammatory Bowel Disease: A Review.
Wark G; Samocha-Bonet D; Ghaly S; Danta M
Nutrients; 2020 Dec; 13(1):. PubMed ID: 33396537
[TBL] [Abstract][Full Text] [Related]
8. The epidemiology and the pathogenesis of inflammatory bowel disease.
Karlinger K; Györke T; Makö E; Mester A; Tarján Z
Eur J Radiol; 2000 Sep; 35(3):154-67. PubMed ID: 11000558
[TBL] [Abstract][Full Text] [Related]
9. Current therapy of inflammatory bowel disease in children.
Rufo PA; Bousvaros A
Paediatr Drugs; 2006; 8(5):279-302. PubMed ID: 17037946
[TBL] [Abstract][Full Text] [Related]
10. Diet therapy for inflammatory bowel diseases: The established and the new.
Durchschein F; Petritsch W; Hammer HF
World J Gastroenterol; 2016 Feb; 22(7):2179-94. PubMed ID: 26900283
[TBL] [Abstract][Full Text] [Related]
11. [Immune-mediated inflammatory diseases in patients with inflammatory bowel disease. Baseline data from the Aquiles study].
Marín-Jiménez I; García Sánchez V; Gisbert JP; Lázaro Pérez Calle J; Luján M; Gordillo Ábalos J; Tabernero S; Juliá B; Romero C; Cea-Calvo L; García-Vicuña R; Vanaclocha F
Gastroenterol Hepatol; 2014 Nov; 37(9):495-502. PubMed ID: 24717523
[TBL] [Abstract][Full Text] [Related]
12. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
13. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
14. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
[TBL] [Abstract][Full Text] [Related]
15. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
[TBL] [Abstract][Full Text] [Related]
16. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
[TBL] [Abstract][Full Text] [Related]
18. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases.
Halling ML; Kjeldsen J; Knudsen T; Nielsen J; Hansen LK
World J Gastroenterol; 2017 Sep; 23(33):6137-6146. PubMed ID: 28970729
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
